Katy Rezvani, MD Anderson

Re­play part­ners with MD An­der­son’s Katy Rez­vani, heads to clin­ic with new TCR NK cell com­pa­ny

Hub-and-spoke com­pa­ny Re­play has launched a new cell ther­a­py com­pa­ny called Sye­na, co-found­ed by NK cell leader Katy Rez­vani of the Uni­ver­si­ty of Texas MD An­der­son Can­cer Cen­ter.

Sye­na plans to put Rez­vani’s T cell re­cep­tor nat­ur­al killer, or TCR NK, cell ther­a­pies in­to a Phase I tri­al in the sec­ond quar­ter of the year. That would make it the first to bring a TCR NK cell ther­a­py in­to the clin­ic, Rez­vani told End­points News. Rez­vani added that they’re work­ing on an IND pack­age to sub­mit to the FDA, which should hap­pen “in the next cou­ple of weeks or so.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.